Our findings reveal a significant involvement of both Aldh1a1+ and Calb1+ SNc DANs in motor control and learning, highlighting both molecularly distinct SNc DAN subtypes as potential therapeutic targets for treating PD-related movement disorders. This evidence concerns the gene ALDH1A1 and Parkinson disease.